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Abstract: Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)
is emerging as an important modality for imaging patients with prostate cancer (PCa). As with any
imaging modality, indeterminate findings will arise. The PSMA reporting and data system (PSMA-
RADS) version 1.0 codifies indeterminate soft tissue findings with the PSMA-RADS-3A moniker.
We investigated the role of point-spread function (PSF) reconstructions on categorization of PSMA-
RADS-3A lesions. Methods: This was a post hoc analysis of an institutional review board approved
prospective trial. Around 60 min after the administration of 333 MBq (9 mCi) of PSMA-targeted
18F-DCFPyL, patients underwent PET/computed tomography (CT) acquisitions from the mid-thighs
to the skull vertex. The PET data were reconstructed with and without PSF. Scans were categorized
according to PSMA-RADS version 1.0, and all PSMA-RADS-3A lesions on non-PSF images were re-
evaluated to determine if any could be re-categorized as PSMA-RADS-4. The maximum standardized
uptake values (SUVs) of the lesions, mean SUVs of blood pool, and the ratios of those values were
determined. Results: A total of 171 PSMA-RADS-3A lesions were identified in 30 patients for whom
both PSF reconstructions and cross-sectional imaging follow-up were available. A total of 13/171
(7.6%) were re-categorized as PSMA-RADS-4 lesions with PSF reconstructions. A total of 112/171
(65.5%) were found on follow-up to be true positive for PCa, with all 13 of the re-categorized lesions
being true positive on follow-up. The lesions that were re-categorized trended towards having higher
SUVmax-lesion and SUVmax-lesion/SUVmean-blood-pool metrics, although these relationships were
not statistically significant. Conclusions: The use of PSF reconstructions for 18F-DCFPyL PET can
allow the appropriate re-categorization of a small number of indeterminate PSMA-RADS-3A soft
tissue lesions as more definitive PSMA-RADS-4 lesions. The routine use of PSF reconstructions for
PSMA-targeted PET may be of value at those sites that utilize this technology.
Keywords: prostate-specific membrane antigen; reporting and data system; positron emission
tomography
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1. Introduction
Prostate cancer (PCa) is the most common noncutaneous malignancy in men as well as
the second most common cause of cancer death in men in the U.S.A. [1]. The high incidence
of PCa has been a driving force for the development of new imaging techniques to improve
staging and re-staging. Although conventional imaging with computed tomography (CT)
and bone scan can adequately stage patients with widespread metastatic disease, the
introduction of radiopharmaceuticals that bind the prostate-specific membrane antigen
(PSMA), for targeted positron emission tomography/computed tomography (PET/CT),
has facilitated the detection of small-volume lesions that can significantly alter treatment
planning [2].
PSMA is a class II transmembrane glycoprotein that is a valuable target for imaging
and therapy, as it is significantly overexpressed on malignant prostate cells [3]. Among
the emerging indications for PSMA PET is the evaluation of patients with biochemical
recurrence (BCR) after initial curative-intent therapy [4] and the identification of men with
oligometastatic PCa (typically being defined as ≤5 sites of distant disease) [5]. Sensitive
lesion detection in men with BCR or oligometastatic disease is desired for directing further
treatment, which might include targeted radiotherapy or surgery [6].
Given the increased use of such therapies for limited volume recurrent/metastatic
disease, the confident characterization of lesions on PSMA PET is an important clinical
need. For this reason, we developed the PSMA-RADS version 1.0 scoring system, which
includes indeterminate categories for lesions that cannot be definitively ascertained to be
PCa [7–10]. One such category is PSMA-RADS-3A, which describes lymph nodes and other
soft tissue lesions that would be in the typical distribution of PCa but are small and have
low-level uptake. We have previously found that approximately 75% of PSMA-RADS-3A
lesions will manifest as true positive sites of PCa on follow-up imaging [9]. Improvements
in the evaluation of these small and generally subtle lesions so that they could be more
definitively assigned as benign or malignant findings would be of value to guide accurate
therapy planning.
Modern image reconstruction techniques, including point-spread function (PSF) re-
construction, can lead to improved signal-to-noise ratio and conspicuity of small or subtle
lesions [11]. Hence, the aim of this study was to evaluate if PSF reconstructions for 18F-
DCFPyL PET/CT affect the characterization of PSMA-RADS-3A lesions.
2. Materials and Methods
2.1. Patient Population
Patients with a history of pathologically diagnosed PCa who had undergone an 18F-
DCFPyL PET/CT scan on an institutional review board approved prospective research
protocol (ClinicalTrials.gov (accessed on 1 January 2021) NCT02825875) were screened as
part of this post hoc analysis to identify patients with at least one PSMA-RADS-3A lesion.
All patients had signed written, informed consent to participate in the original research
trial. Patients were imaged under the auspices of a US Food and Drug Administration In-
vestigational New Drug Application (IND 121064). Clinical and demographic information,
including age, serum prostate-specific antigen (PSA) levels, and PCa treatment history,
was collected.
2.2. Image Acquisition
The radiosynthesis of 18F-DCFPyL was performed as previously described [12]. Im-
ages were acquired in a manner consistent with prior studies [13]. In brief, all patients were
asked to refrain from eating or drinking (other than water and medications) for at least 4 h
before the intravenous injection of approximately 333 MBq (9 mCi) of 18F-DCFPyL. One
hour after the injection, whole-body PET/CT was performed (from the midthighs to the
vertex of the skull) on one of two clinical scanners. Patients included in the final analysis
were imaged on a 128-slice Biograph mCT scanner (Siemens) and reconstructed with both a
standard ordered subset expectation maximization (OSEM) algorithm and OSEM with PSF.
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The standard reconstruction algorithm involved 3D OSEM with time-of-flight, 2 iterations,
21 subsets, and a 5 mm Gaussian filter. The higher spatial resolution PSF reconstruction
involved 3D OSEM with time-of-flight and PSF modelling, 2 iterations, 21 subsets, and no
post-reconstruction filter. CT (40 effective mAs) was utilized for attenuation correction.
2.3. Image Analysis
18F-DCFPyl PET/CT scans reconstructed with OSEM but without PSF were centrally
reviewed by an experienced reader (HWC), and lesions were characterized according to
PSMA-RADS version 1.0. A second experienced reader (SPR) verified the lesion charac-
terizations on OSEM without PSF and then re-characterized the PSMA-RADS-3A lesions
with OSEM with PSF. As defined in the original description of the PSMA-RADS 1.0 scoring
system, the central reviewers considered PSMA-RADS-3A lesions to be lymph node or soft
tissue findings that had subtle radiotracer uptake (approximately blood pool or slightly
higher) and that were in a typical pattern of distribution for PCa, such as the pelvis and
retroperitoneum [7,8]. Additionally, radiotracer uptake in the mediastinum and left supra-
clavicular space in patients with more advanced disease was considered as typical sites
of PCa spread. Lesions that appeared more conspicuous with PSF were re-categorized as
PSMA-RADS-4: a category that signifies distinct uptake in un-enlarged lymph nodes or
other morphologically normal soft tissue structures and that is highly suggestive of the
presence of PCa.
For those patients for whom it was available, follow-up cross-sectional imaging was
reviewed in order to establish which PSMA-RADS-3A lesions developed into true positive
sites of disease. No specific limitations were set on the type of follow-up imaging that could
be used, and imaging included repeat 18F-DCFPyL PET/CT, 18F-fluciclovine PET/CT, CT,
or MRI. Lesions that were determined on follow-up to be suggestive of the presence of PCa
met at least one of the following criteria, adapted from [9]:
1. Follow-up PET/CT imaging with 18F-DCFPyL with significantly increasing or decreas-
ing uptake (defined as a change of 30% from baseline) after therapy OR significantly
increased uptake during observation. If the follow-up PET/CT was performed with
18F-fluciclovine, focal uptake in a lesion in concordance with the read paradigm [14]
for that agent was taken as evidence of true positivity.
2. Anatomic imaging with CT or MRI demonstrating a ≥2 mm increase in the long axis
diameter of the lesion during a period of observation or a decrease in the lesion long
axis diameter of ≥2 mm after beginning PCa treatment.
In addition to PSMA-RADS version 1.0 categorization, the SUVmax corrected for lean
body mass for all of the lesions and the SUVmean of blood pool (determined by a 3 cm sphere
in the ascending aorta) were measured. The ratios of SUVmax of each lesion corrected for
the SUVmean of blood pool (SUVmax-lesion/SUVmean-blood-pool) were calculated.
2.4. Statistical Analysis
Descriptive statistics were utilized for this post hoc analysis. Patient demographic
and clinical information are given as medians with ranges or percentages, as appropriate.
SUVmax, SUVmean, and SUVmaxlesion/SUVmean-blood-pool are expressed as medians with
interquartile ranges (IQRs). Median values were compared using the Mann–Whitney U
test with p-values < 0.05 considered significant. Statistical analysis was performed with
PASW Statistics 17.0 (Chicago, IL, USA).
3. Results
3.1. Patients
Clinical and imaging parameters of 275 patients were screened. Of those, 89 patients
were categorized as having at least one PSMA-RADS-3A lesion on standard clinical re-
constructions of their 18F-DCFPyL PET/CT scans. Thirty of those patients were found
to (1) have been imaged on the Siemens Biograph mCT scanner with PSF reconstruction
images of their 18F-DCPFyL PET/CTs available in the picture archiving and communica-
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tion system (PACS) and (2) had adequate follow-up cross-sectional imaging to evaluate for
potential changes over time in the PSMA-RADS-3A lesions.
Those 30 patients were included in the presented analysis. Their median age was
72.5 (range 59–81) and median serum PSA at the time of imaging was 3.8 (range 0.2–43.9).
Twenty-two (73.3%) underwent imaging for biochemical recurrence or PSA persistence
following local therapy, 4 (13.3%) underwent imaging for initial PCa staging, and 4 (13.3%)
underwent imaging for evaluation of metastatic disease. With regard to available follow-up
imaging, 20 (66.7%) underwent diagnostic abdomen/pelvis CT scans, 6 (20.0%) underwent
repeat 18F-DCFPyL PET/CT, 3 (10.0%) underwent 18F-fluciclovine PET/CT, and 1 (3.3%)
underwent a pelvic MRI. Follow-up imaging was performed at a median of 11 months
(range: 2–36 months) post initial 18F-DCFPyL PET/CT. Selected demographic and clinical
information of the study cohort are included in Table 1.
















- Salvage PLND 7%
- Chemotherapy 20%
- Observation 13%
Abbreviations: ADT = androgen deprivation therapy; PLND = pelvic lymph node dissection.
3.2. Image Analysis
Among the 30 patients included in this study, a total of 171 lesions were designated
as PSMA-RADS-3A (median 4 per patient, range 1–23), all of which were lymph nodes.
Of these lesions, 13/171 (7.6%) demonstrated visual changes with PSF reconstructions
such that they were re-categorized as PSMA-RADS-4 (Figure 1). A total of 112/171 (65.5%)
lesions were found on follow-up imaging to be indicative of PCa, 32/112 (28.6%) by
category 1 above, and 80/112 (71.4%) by category 2 above. A total of 13/13 (100.0%) of
the re-categorized lesions were found to be true positive on follow-up imaging, whereas
99/158 (62.7%) lesions that were still considered indeterminate on the PSF reconstructions
were found to be true positive on follow-up.
Uptake characteristics of lesions are summarized in Figures 2 and 3. The analyses
based on SUVmax-lesion and SUVmean-blood-pool demonstrated that SUVs were generally
higher on PSF reconstructed images. The SUVmax-lesion median value for all lesions on
non-PSF images was 1.7 (IQR 1.2–2.1). The SUVmax-lesion median value all lesions on PSF
images was 1.8 (IQR 1.4–2.5). The SUVmean-blood-pool median on non-PSF images was 1.4
(IQR 1.3–1.5) and on PSF images was 1.4 (IQR 1.3–1.6). SUVmax-lesion/SUVmean-blood-pool
median for all lesions on non-PSF images was 1.1 (IQR 0.8–1.6). SUVmax-lesion/SUVmean-
blood-pool for all lesions on PSF images was 1.3 (IQR 0.9–1.9).
For the 13 PSMA-RADS-3A lesions that were re-categorized to PSMA-RADS-4, the
SUVmax-lesion and SUVmax-lesion/SUVmean-blood-pool on both non-PSF and PSF images
were generally higher than those lesions that were not re-categorized (Figure 2), although
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these differences were not statistically significant (p = 0.085–0.216). Similar to our prior
findings [9], there was no difference in the SUVmax-lesion and SUVmax-lesion/SUVmean-
blood-pool values between those lesions that were true positive and those that were not
confirmed to be true positive (Figure 2, p = 0.198–0.811). The distributions of uptake
in the different lesion categories overlapped on both non-PSF and PSF reconstructed
images (Figure 3).
Figure 1. A 68-year-old man with history of prostatectomy and adjuvant chemohormonal therapy, now with an increase
in prostate-specific antigen (PSA) to 0.3. (A) 18F-DCFPyL positron emission tomography (PET) and (B) PET/computed
tomography (CT) axial images without point-spread function (PSF) demonstrating bilateral PSMA-RADS-3A pelvic lymph
nodes (thin and thick red arrows, maximum standardized uptake value (SUVmax) 1.2 on the right and 1.5 on the left). (C)
18F-DCFPyL PET and (D) PET/CT axial images with PSF show that the right pelvic PSMA-RADS-3A lymph node does not
appear significantly more conspicuous (SUVmax 2.2) and that lesion was not re-categorized. However, the lymph node on
the left (SUVmax 2.5) was thought to be more conspicuous and was re-categorized to PSMA-RADS-4.
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Figure 2. Bar graph representation of medians and interquartile ranges for the SUVmax-lesion and SUVmax-lesion/SUVmean-
blood-pool metrics of the PSMA-RADS-3A lesions included in this study. In each bar of the graph, the top number is
the median and the interquartile ranges are listed below. Note the trends towards higher SUVs of the lesions that were
re-categorized as PSMA-RADS-4 (dark grey), although none of these relationships reached statistical significance (i.e.,
all p > 0.05). SUV = standardized uptake value; nPSF = non-point-spread function; BP = blood-pool; PSF = point-spread
function; LN = lymph node.
Figure 3. Distributions of SUVmax-lesion and SUVmax-lesion/SUVmean-blood-pool for the different categories of lymph
nodes included in this study. The outlier high uptake values were related to overlap of other high uptake structures in the
manual segmentations of the lesions. SUV = standardized uptake value; nPSF = non-point-spread function; BP = blood-pool;
PSF = point-spread function; LN = lymph node.
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4. Discussion
PSMA-targeted PET has been rapidly adopted around the world for PCa imaging
given its high sensitivity and specificity for the identification of sites of disease [15,16].
However, as with any imaging modality, there are indeterminate findings that belie easy
categorization [17]. The preponderance of studies on PSMA-targeted PET imaging has
been retrospective, further hindering the ability of readers to know how best to guide
management of indeterminate findings, although large prospective studies are starting to
appear in the literature [18].
In this study, PSF reconstruction methods for 18F-DCFPyL PET/CT scans were eval-
uated in terms of characterization of indeterminate PSMA-RADS-3A lesions. We found
that PSF reconstructions can increase the contrast and activity concentration within PSMA-
RADS-3A lesions, and that based on a visual analysis, there was a subset of lesions that
were changed to the more definitive category of PSMA-RADS-4 (7.6%). Of those lesions that
were determined to change to PSMA-RADS-4 on the PSF-reconstructed images, all were
determined to be true positive on follow-up imaging. This suggests that PSF reconstruc-
tions can increase confidence in the characterization of a small number of indeterminate
lesions on PSMA-targeted PET scans, and that confidence does not come at the cost of
decreased specificity. It should be noted that the lesions that were re-categorized tended
to have higher SUVmax-lesion and SUVmax-lesion/SUVmean-blood-pool than those lesions
that were not re-categorized (although the trend did not reach significance), suggesting
that careful segmentation and determination of semi-quantitative parameters may aid in
PSMA-RADS classification and that it may not be optimized as a purely visual method of
lesion categorization.
Regardless of reconstruction methodology, the vast majority of indeterminate soft
tissue lesions on PSMA PET will remain indeterminate. As we have previously shown [9],
and consistent with the present work, a sizable majority of indeterminate soft tissue lesions
will be true positive on follow-up (65.5% in this study, similar to the 75.0% reported in [9]),
and it may be prudent to include such lesions in the planning of salvage therapies, such
as stereotactic body radiation therapy for oligometastatic disease [19]. A subset of lesions
that could not be confirmed as true positive may still represent sites of PCa; however,
they did not undergo the changes that we had designated a priori as indicative of true
positive lesions. It is likely that artificial intelligence algorithms will be able to leverage the
large amounts of scan data to eventually aid in the definitive characterization of otherwise
indeterminate findings [20].
An important limitation of this study is the lack of histopathologic confirmation of
PSMA-RADS-3A lesions. Such lesions on 18F-DCFPyL PET scans are often smaller than
1 cm, making biopsy impossible to perform. Thus, we were required to rely upon imaging
follow-up to define a true positive lesion. Other limitations of our study include its post
hoc design and small sample size of only 30 patients. Nonetheless, a large number of
lesions were analyzed allowing for confidence in our findings. Further, the central review
that was utilized was primarily driven by one reader with a second, corroborating reader;
this could have introduced bias. Lastly, for small lesions with subtle uptake, the physical
differences in image quality between 18F and 68Ga may be relevant, and it is uncertain if
the findings in this study would directly apply to 68Ga-labeled PSMA agents. Certainly,
given these limitations, further study of this topic is warranted.
5. Conclusions
We evaluated the impact of PSF reconstruction for 18F-DCFPyL PET/CT on indetermi-
nate PSMA-RADS-3A lesions in patients with PCa. A small number of lesions became more
definitively characterized with the addition of PSF, and all of those that were re-categorized
were found to be true positive on follow-up. We conclude that PSF reconstructions for
PSMA-targeted PET may appropriately increase confidence in the characterization of a
small, yet clinically significant, number of otherwise indeterminate lesions.
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